title: Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
abstract: OBJECTIVE
  To compare the immunologic effectiveness of raltegravir-maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M-) in treatment-experienced patients in clinical practice.
  
  
  METHODS
  We conducted a retrospective study of treatment-experienced HIV-infected adults receiving either R+M+- or R+M--based therapy. Longitudinal CD4 counts were analyzed using a linear mixed model.
  
  
  RESULTS
  One hundred and fifty-six patients were included in the analysis, of whom 32 were receiving R+M+ and 124 R+M-. Mean baseline CD4 counts in patients on R+M+ and R+M- were 463.8 and 442.3 cells/mm(3), respectively (P = .67). In multivariable mixed models, a baseline viral load ≥50 copies/mL was significantly associated with CD4 change during follow-up (P < .0001). No difference between R+M+ and R+M- was observed during follow-up (P = .81).
  
  
  CONCLUSIONS
  CD4 cell recovery was similar among patients receiving either R+M+- or R+M--based therapy during a 24-month period of follow-up.
authors.affiliation: 1University of Toronto, Toronto, Ontario, Canada.
authors.forename: Tony
authors.initials: T
authors.lastname: Antoniou
authors.forename: Graham
authors.initials: G
authors.lastname: Smith
authors.forename: Desheng
authors.initials: D
authors.lastname: Su
authors.forename: Janet M
authors.initials: JM
authors.lastname: Raboud
authors.forename: Derek
authors.initials: D
authors.lastname: Lee
authors.forename: Colin
authors.initials: C
authors.lastname: Kovacs
authors.forename: Jason
authors.initials: J
authors.lastname: Brunetta
authors.forename: David
authors.initials: D
authors.lastname: Fletcher
authors.forename: Fred
authors.initials: F
authors.lastname: Crouzat
authors.forename: Mona
authors.initials: M
authors.lastname: Loutfy
mesh_terms: D019380:Anti-HIV Agents / Q000276:immunology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D011760:Pyrrolidinones / Q000276:immunology* / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D012189:Retrospective Studies; D014230:Triazoles / Q000276:immunology* / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D011760:Pyrrolidinones; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc